How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
One-stop Pharmacy Research CDMO Market
- By Service Type: Formulation Development, Analytical Development and Testing, Clinical Trial Material Manufacturing, Commercial Manufacturing, Regulatory Support Services
- By Drug Type: Small Molecule Drugs, Biologics, Biosimilars, Advanced Therapy Medicinal Products (ATMPs), Vaccines
- By Dosage Form: Oral Solid Dosage Forms, Injectables, Topical Formulations, Inhalation Products, Ophthalmic Preparations
- By Client Type: Pharmaceutical Companies, Biotechnology Firms, Generic Drug Manufacturers, Contract Research Organizations (CROs), Academic and Research Institutions
- By Scale of Operation: Preclinical and Early Phase Development, Clinical Phase I/II Manufacturing, Clinical Phase III and Commercial Scale Manufacturing
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Formulation Development leads By Service Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 300 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.183 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.191 →
Full report · locked preview
Everything inside the One-stop Pharmacy Research CDMO Market report
A complete, evidence-based study - 12 chapters and 126 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Service Type 5
Drug Type 5
Dosage Form 5
Client Type 5
Scale of Operation 3
Companies profiled
Catalent Pharma Solutions
Lonza Group
Patheon (Thermo Fisher Scientific)
Recipharm
Fujifilm Diosynth Biotechnologies
Samsung Biologics
WuXi AppTec
Boehringer Ingelheim BioXcellence
CordenPharma
AMRI (Albany Molecular Research Inc.)
Siegfried Holding AG
Bachem Holding AG
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Catalent Pharma Solutions
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Lonza Group
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Patheon (Thermo Fisher Scientific)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Recipharm
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Fujifilm Diosynth Biotechnologies
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Samsung Biologics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →WuXi AppTec
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Boehringer Ingelheim BioXcellence
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →CordenPharma
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →AMRI (Albany Molecular Research Inc.)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Siegfried Holding AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Bachem Holding AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Evonik Industries
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Cambrex Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Vetter Pharma International
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$3,208M by 2033 · 9.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Formulation Development49.9
- Analytical Development and Testing12.2
- Clinical Trial Material Manufacturing13.9
- Commercial Manufacturing14.4
- Regulatory Support Services9.5
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$515.3M → $964.4M · 8.1%
Europe$359.1M → $709.2M · 8.9%
Asia Pacific$327.9M → $600.8M · 7.9%
Latin America$203.0M → $394.4M · 8.7%
Middle East and Africa$156.1M → $350.6M · 10.6%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →9.382026
9.382027
9.392028
9.402029
9.412030
9.422031
9.442032
9.452033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Catalent Pharma Solutions17.1
- Lonza Group22.3
- Patheon (Thermo Fisher Scientific)7.4
- Recipharm10.3
- Fujifilm Diosynth Biotechnologies10.6
- Samsung Biologics4.2
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Service Type23.1%
Drug Type24.4%
Dosage Form15.5%
Client Type11.6%
Scale of Operation25.4%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.9
- Europe23.5
- Asia Pacific19.9
- Latin America13.1
- Middle East and Africa11.6
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Catalent Pharma Solutions | 80 | 90 | 93 | 88 | 97 | 83 | 89 |
| Lonza Group | 81 | 69 | 79 | 83 | 85 | 88 | 81 |
| Patheon (Thermo Fisher Scientific) | 73 | 78 | 87 | 87 | 67 | 86 | 80 |
| Recipharm | 71 | 76 | 65 | 71 | 73 | 67 | 71 |
| Fujifilm Diosynth Biotechnologies | 54 | 67 | 77 | 56 | 62 | 55 | 62 |
| Samsung Biologics | 64 | 68 | 55 | 54 | 58 | 68 | 61 |
| WuXi AppTec | 45 | 56 | 48 | 43 | 52 | 42 | 48 |
| Boehringer Ingelheim BioXcellence | 53 | 56 | 39 | 48 | 46 | 49 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Catalent Pharma Solutions
- Lonza Group
- Patheon (Thermo Fisher Scientific)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Catalent Pharma Solutions | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Lonza Group | ✓ | ◐ | ✓ | ✓ | ◐ | ✓ |
| Patheon (Thermo Fisher Scientific) | ◐ | ✓ | ◐ | ◐ | ◐ | ✓ |
| Recipharm | ◐ | ✓ | − | ◐ | ✓ | − |
| Fujifilm Diosynth Biotechnologies | − | ◐ | ◐ | ◐ | ◐ | − |
| Samsung Biologics | ◐ | ✓ | − | ◐ | − | − |
| WuXi AppTec | − | ◐ | − | − | ◐ | − |
| Boehringer Ingelheim BioXcellence | ◐ | ◐ | − | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Catalent Pharma Solutions89
2Lonza Group81
3Patheon (Thermo Fisher Scientific)80
4Recipharm71
5Fujifilm Diosynth Biotechnologies62
6Samsung Biologics61
7Boehringer Ingelheim BioXcellence49
8WuXi AppTec48
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Catalent Pharma SolutionsLonza GroupPatheon (Thermo Fisher Scientific)
Challenger1
Strong scale, closing on the leaders.
Recipharm
Contender2
Focused players with pockets of strength.
Fujifilm Diosynth BiotechnologiesSamsung Biologics
Niche2
Specialists in a single segment or region.
WuXi AppTecBoehringer Ingelheim BioXcellence
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Service Type in North America, then scale across One-stop Pharmacy Research CDMO Market — a $230M beachhead inside a $3.65B market.
Beachhead (SOM)$230Mobtainable near-term
Serviceable (SAM)$1.25Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Formulation Development
Best fit — highest urgency & budget in Service Type.
Economic buyer79 fit
Analytical Development and Testing
Strong fit — clear ROI and a fast path to value.
End user68 fit
Clinical Trial Material Manufacturing
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Service Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Drug Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Dosage Form
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales41%
Partner / channel29%
Digital / self-serve22%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Service Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win One-stop Pharmacy Research CDMO Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified45%
Sales qualified24%
Evaluation14%
Closed-won7%
$10.5KCAC
$36KLTV
3.4:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
One-stop Pharmacy Research CDMO Market is a durable-growth opportunity — $5.85B by 2033, compounding at 8.7%.
TAM · 2025$3.01Btoday
TAM · 2033$5.85Bforecast
CAGR8.7%2027–2033
Cumulative$38.6Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.85BTotal addressable market
SAM$2.37BServiceable available market
SOM$504MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →8.7% CAGR
Demand compounds through 2033, outpacing GDP across Service Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Service Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.85BLarge & growingTAM by 2033 at 8.7% CAGR
$2.37BServiceable nowreachable with today’s model
$504MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.56BBear5.6% CAGR
$5.85BBase8.7% CAGR
$7.49BBull11.4% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Drug Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
One-stop Pharmacy Research CDMO Market — a $4.28B market by 2033. Plan: grow share from 8.4% to 13.9%.
Market size · 2033$4.28Btotal addressable
Market CAGR3.9%2027–2033
Target share13.9%from 8.4% today
Revenue ambition$594Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.4% | 13.9% | On track |
| Revenue | $378M | $594M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Behind |
| Gross margin | 36.9% | 45.7% | On track |
| Customer retention | 89.7% | 96.8% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Service Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Drug Type capability
A defensible second engine — invest in Drug Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Service Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Drug Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $76M capacity & capability investment
- Greenlight bolt-on M&A in Drug Type
- Authorise North America expansion plan
- Fund R&D program for Service Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossBehind
- Input-cost & supply riskAhead
- Regulatory / policy changeAhead
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the One-stop Pharmacy Research CDMO Market conversation — a $5.97B market you can size, segment and defend in minutes.
Market size · 2033$5.97Btotal opportunity
Growth6.5%CAGR to 2033
Addressable buyers1,267+accounts in scope
Typical ROI5.1×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Service Type
Goal Grow share in Service Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.1×return on cost, year one
< 3 mopayback period
$88K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Catalent Pharma SolutionsLonza GroupPatheon (Thermo Fisher Scientific)RecipharmFujifilm Diosynth BiotechnologiesSamsung BiologicsWuXi AppTecBoehringer Ingelheim BioXcellence+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your One-stop Pharmacy Research CDMO Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
One-stop Pharmacy Research CDMO Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →One-Step RT-PCR Kit Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportOne-Step Prostate Specific Antigen Test Kit Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportOne-Step HIV-HCV-HBsAg-syphilis Combination Test Market
Market size, share, segmentation and regional forecast.
$672M market · 2025 base year
View reportOne-Piece Toric Intraocular Lens Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportOne-Piece Stoma System Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportOne-piece Soft Capsule Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportOne-piece Posterior Chamber Intraocular Lens Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportOne Piece Ostomy Bag Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportOne-piece Capsules Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportO'Neil Intermittent Urinary Catheter Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportOne-Cell Permeability Test System Market
Market size, share, segmentation and regional forecast.
$526M market · 2025 base year
View reportOndansetron Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.